Authors have pulled a paper on an antifungal drug that is potentially toxic because it lacked final approval from their institution.
The study describes a patient who had experienced liver toxicity after taking voriconazole. During the study, the authors re-administered the drug to the patient using “a slow dose titration.” But their institution didn’t approve the study before it was published online.
Here’s the retraction note for “Successful Rechallenge with Voriconazole following Medication-Induced Hepatotoxicity,” published in Antimicrobial Agents and Chemotherapy. Continue reading Antifungal drug paper didn’t have institution’s approval
